Lugar de publicación

• Systematic literature review of cross-protective effect of HPV vaccines based on data from randomized clinical trials and real-world evidence.  39:2224-2236. 2021
• Systematic literature review of neutralizing antibody immune responses to non-vaccine targeted high-risk HPV types induced by the bivalent and the quadrivalent vaccines.  39:2214-2223. 2021
• Evaluating the immunogenicity of chemically-synthesised peptides derived from foot-and-mouth disease VP1, VP2 and VP3 proteins as vaccine candidates.  38:3942-3951. 2020
• Cryptosporidium spp. CP15 and CSL protein-derived synthetic peptides’ immunogenicity and in vitro seroneutralisation capability.  36:6703-6710. 2018
• Immune protection-inducing protein structures (IMPIPS) against malaria.  33:7525-7537. 2015
• Gauche⁺ side-chain orientation as a key factor in the search for an immunogenic peptide mixture leading to a complete fully protective vaccine.  32:2117-2126. 2014
• Rh1 high activity binding peptides inhibit high percentages of Plasmodium falciparum FVO strain invasion.  31:1830-1837. 2013
• A single amino acid change in the Plasmodium falciparum RH5 (PfRH5) human RBC binding sequence modifies its structure and determines species-specific binding activity.  30:637-646. 2012
• 3D structure determination of STARP peptides implicated in P. falciparum invasion of hepatic cells.  28:4989-4996. 2010
• Sequences of the Plasmodium falciparum cytoadherence-linked asexual protein 9 implicated in malaria parasite invasion to erythrocytes.  28:2653-2663. 2010
• Characterization and antigenicity of the promising vaccine candidate Plasmodium vivax 34 kDa rhoptry antigen (Pv34).  28:415-421. 2009
• Characterization and antigenicity of the promising vaccine candidate Plasmodium vivax 34kDa rhoptry antigen (Pv34)..  28:415-421. 2009
• Vaccination with recombinant Plasmodium vivax MSP-10 formulated in different adjuvants induces strong immunogenicity but no protection.  28:7-13. 2009
• Synthetic peptides from conserved regions of the Plasmodium falciparum early transcribed membrane and ring exported proteins bind specifically to red blood cell proteins.  27:6877-6886. 2009
• Immunogenicity and protection-inducing ability of recombinant Plasmodium vivax rhoptry-associated protein 2 in Aotus monkeys.  27:2870-2876. 2009
• Identification of conserved erythrocyte binding regions in members of the Plasmodium falciparum Cys6 lipid raft-associated protein family..  3953-3962. 2009
• Structural and immunological analysis of circumsporozoite protein peptides: a further step in the identification of potential components of a minimal subunit-based, chemically synthesised antimalarial vaccine.  26:6908-6918. 2008
• Peptides derived from the Mycobacterium tuberculosis Rv1490 surface protein implicated in inhibition of epithelial cell entry.  26:4387-4395. 2008
• Studies of Plasmodium falciparum rhoptry-associated membrane antigen (RAMA) protein peptides specifically binding to human RBC.  26:853-862. 2008
• Synthetic vaccine update: Applying lessons learned from recent SPf66 malarial vaccine physicochemical, structural and immunological characterization.  25:4487-4501. 2007
• Evidence supporting the hypothesis that specifically modifying a malaria peptide to fit into HLA-DRβ1 *03 molecules induces antibody production and protection.  1579-1587. 2005
• Sporozoite and liver stage antigen Plasmodium falciparum peptides bind specifically to human hepatocytes.  22:1150-1156. 2004
• Specific erythrocyte binding capacity and biological activity of Plasmodium falciparum-derived rhoptry-associated protein 1 peptides.  22:1054-62. 2004
• Induction and displacement of an helix in the 6725 SERA peptide analogue confers protection against P. falciparum malaria..  22:1281-1289. 2004
• Expression, polymorphism analysis, reticulocyte binding and serological reactivity of two Plasmodium vivax MSP-1 protein recombinant fragments.  21:1033-1043. 2003